

July 27, 2016

To

National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C1, 'G' Block, Bandra-Kurla Complex Bandra (East), Mumbai 400 051. BSE Limited Floor 25, P.J. Towers Dalal Street Mumbai 400 001.

Dear Sirs,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

(Scrip Code: RPGLIFE / 532983)

This is to inform you that the Board of Directors of the Company at its meeting held on July 27, 2016, has approved the acquisition of Trade Marks from Sun Pharmaceutical Industries Limited and its subsidiary.

A Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed.

Kindly take the same on records.

Thanking you,

Yours faithfully, For RPG Life Sciences Limited

Rajesh Shirambekar Head - Legal & Company Secretary

Encl: As above







CIN: L24232MH2007PLC169354

DISLOSURE UNDER REGULATION 30 OF SEBI (LODR) REGULATIONS, 2015

Agreements which are binding and not in normal course of business

Sr.	Disclosure	Details
a)	name(s) of parties with whom the agreement is entered	Sun Pharmaceutical Industries Limited
b)	purpose of entering into the agreement	Acquisition of Trade Marks
c)	size of agreement	Rs.41 crores
d)	shareholding, if any, in the entity with whom the agreement is executed	NIL
e)	significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Acquisition of Trade Marks as per Assets Purchase Agreement dated July 27, 2016
f)	whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	No
g)	whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length";	No
h)	in case of issuance of shares to the parties, details of issue price, class of shares issued;	Not Applicable
i)	in case of loan agreements, details of lender, nature of the loan, total amount of loan granted, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders for such loan;	Not Applicable
j)	any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc;	Not Applicable
k)	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable